US5656295A
(en)
*
|
1991-11-27 |
1997-08-12 |
Euro-Celtique, S.A. |
Controlled release oxycodone compositions
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5681585A
(en)
*
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
IL109460A
(en)
|
1993-05-10 |
1998-03-10 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP0647448A1
(en)
*
|
1993-10-07 |
1995-04-12 |
Euroceltique S.A. |
Orally administrable opioid formulations having extended duration of effect
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US6210714B1
(en)
*
|
1993-11-23 |
2001-04-03 |
Euro-Celtique S.A. |
Immediate release tablet cores of acetaminophen having sustained-release coating
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
†
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5558879A
(en)
*
|
1995-04-28 |
1996-09-24 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
ES2200158T3
(es)
*
|
1996-03-08 |
2004-03-01 |
Nycomed Danmark Aps |
Cmpuesto de dosificacion de unidades multiples, de liberacion modificada.
|
AU3404997A
(en)
*
|
1996-05-31 |
1998-01-05 |
Euro-Celtique S.A. |
Sustained release oxycodone formulations with no fed/fast effect
|
JPH1050306A
(ja)
*
|
1996-07-31 |
1998-02-20 |
Toyota Autom Loom Works Ltd |
水素吸蔵合金電極の製造方法
|
DE19710008A1
(de)
*
|
1997-03-12 |
1998-09-17 |
Basf Ag |
Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
|
RS49982B
(sr)
*
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
CN1204890C
(zh)
*
|
1997-12-22 |
2005-06-08 |
欧罗赛铁克股份有限公司 |
防止阿片样物质滥用的方法
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
CA2314893C
(en)
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
Opioid agonist/antagonist combinations
|
EP0955048A1
(en)
*
|
1998-03-12 |
1999-11-10 |
Akzo Nobel N.V. |
Making dosage units using low shear granulation
|
IL128818A0
(en)
*
|
1998-03-12 |
2000-01-31 |
Akzo Nobel Nv |
Making dosage units using low shear granulation
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
RU2230556C2
(ru)
*
|
1999-10-29 |
2004-06-20 |
Эро-Селтик, С.А. |
Препаративные формы гидрокодона с контролируемым высвобождением
|
WO2001045668A2
(en)
*
|
1999-12-20 |
2001-06-28 |
Schering Corporation |
Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
|
AU2276801A
(en)
*
|
1999-12-20 |
2001-07-03 |
Schering Corporation |
Extended release oral dosage composition
|
BR0108379A
(pt)
|
2000-02-08 |
2002-11-05 |
Euro Celtique Sa |
Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
|
AU2002227383B2
(en)
|
2000-10-30 |
2004-07-08 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
DE60238756D1
(de)
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
AU2002314968B2
(en)
*
|
2001-06-08 |
2006-12-07 |
Endo Pharmaceuticals, Inc. |
Controlled release dosage forms using acrylic polymer, and process for making the same
|
CA2452872A1
(en)
|
2001-07-06 |
2003-01-16 |
Endo Pharmaceuticals, Inc. |
Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
|
US7276250B2
(en)
*
|
2001-07-06 |
2007-10-02 |
Penwest Pharmaceuticals Company |
Sustained release formulations of oxymorphone
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
AU2002316738B2
(en)
|
2001-07-18 |
2009-01-08 |
Euro-Celtique S.A. |
Pharmaceutical combinations of oxycodone and naloxone
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
WO2003015531A2
(en)
*
|
2001-08-06 |
2003-02-27 |
Thomas Gruber |
Pharmaceutical formulation containing dye
|
HUP0401191A3
(en)
|
2001-08-06 |
2006-11-28 |
Euro Celtique Sa |
Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20040253310A1
(en)
|
2001-09-21 |
2004-12-16 |
Gina Fischer |
Morphine polymer release system
|
EP2957281A1
(en)
|
2001-09-21 |
2015-12-23 |
Egalet Ltd. |
Polymer release system
|
CA2459976A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
PE20030527A1
(es)
|
2001-10-24 |
2003-07-26 |
Gruenenthal Chemie |
Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
|
PT1484056E
(pt)
*
|
2002-02-21 |
2013-10-14 |
Otsuka Pharma Co Ltd |
Preparações de libertação prolongada e processo para a produção das mesmas
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
EP1492506B2
(en)
*
|
2002-04-05 |
2016-06-29 |
Euro-Celtique S.A. |
Matrix for sustained, invariant and independent release of active compounds
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
CA2483655A1
(en)
*
|
2002-04-29 |
2003-11-13 |
Alza Corporation |
Methods and dosage forms for controlled delivery of oxycodone
|
RU2004134728A
(ru)
*
|
2002-05-31 |
2005-06-10 |
Алза Корпорейшн (Us) |
Дозированные формы и композиции для осмотической доставки различных дозировок оксикодона
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
US7399488B2
(en)
*
|
2002-07-05 |
2008-07-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US8557291B2
(en)
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
US20040058946A1
(en)
*
|
2002-07-05 |
2004-03-25 |
Buchwald Stephen L. |
Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
|
US8840928B2
(en)
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US7168140B2
(en)
*
|
2002-08-08 |
2007-01-30 |
Milliken & Company |
Flame resistant fabrics with improved aesthetics and comfort, and method of making same
|
WO2004016618A1
(en)
*
|
2002-08-15 |
2004-02-26 |
Noramco, Inc. |
Oxycodone-hydrochloride polymorhs
|
EP1545468A4
(en)
*
|
2002-09-20 |
2007-06-20 |
Alpharma Inc |
SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
|
SI1551372T1
(en)
*
|
2002-09-20 |
2018-08-31 |
Alpharma Pharmaceuticals Llc |
SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
US9107804B2
(en)
|
2002-12-10 |
2015-08-18 |
Nortec Development Associates, Inc. |
Method of preparing biologically active formulations
|
SI1575569T1
(sl)
|
2002-12-13 |
2010-12-31 |
Durect Corp |
Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
ATE454169T1
(de)
*
|
2003-03-13 |
2010-01-15 |
Controlled Chemicals Inc |
Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
|
EP1782834A3
(en)
*
|
2003-03-13 |
2007-08-01 |
Controlled Chemicals, Inc. |
Oxycodone conjugates with lower abuse potential and extended duration of action
|
EP2301526B1
(en)
|
2003-03-26 |
2016-03-23 |
Egalet Ltd. |
Morphine controlled release system
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
TWI347201B
(en)
*
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
WO2004093819A2
(en)
|
2003-04-21 |
2004-11-04 |
Euro-Celtique, S.A. |
Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
US20060105036A1
(en)
|
2003-05-12 |
2006-05-18 |
Stephen Peroutka |
Threo-dops controlled release formulation
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
ES2592504T3
(es)
*
|
2003-07-17 |
2016-11-30 |
Banner Life Sciences, LLC |
Preparaciones de liberación controlada
|
DE10361596A1
(de)
*
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
DE102004020220A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
PL1658054T3
(pl)
*
|
2003-08-06 |
2007-11-30 |
Gruenenthal Gmbh |
Postać aplikacyjna zabezpieczona przed nadużyciem
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE10336400A1
(de)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
US20050053659A1
(en)
*
|
2003-09-10 |
2005-03-10 |
Pace Gary W. |
Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
|
WO2005034859A2
(en)
*
|
2003-10-03 |
2005-04-21 |
Elite Laboratories Inc. |
Extended release formulations of opioids and method of use thereof
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
WO2005055981A2
(en)
*
|
2003-12-09 |
2005-06-23 |
Euro-Celtique S.A. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
US8883204B2
(en)
*
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
TWI350762B
(en)
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
GB0403098D0
(en)
|
2004-02-12 |
2004-03-17 |
Euro Celtique Sa |
Extrusion
|
PT1729730E
(pt)
|
2004-03-30 |
2009-04-06 |
Euro Celtique Sa |
Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso
|
TW201509943A
(zh)
|
2004-03-30 |
2015-03-16 |
Euro Celtique Sa |
含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
|
US20050226929A1
(en)
*
|
2004-04-12 |
2005-10-13 |
Jianbo Xie |
Controlled release opioid analgesic formulation
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
EP1604667A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
WO2005123042A1
(en)
*
|
2004-06-10 |
2005-12-29 |
Glatt Air Techniques, Inc. |
Controlled release pharmaceutical formulation
|
PT1765292T
(pt)
|
2004-06-12 |
2017-12-29 |
Collegium Pharmaceutical Inc |
Formulações de fármacos dissuasoras de abuso
|
DE102004032049A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
GB2418854B
(en)
*
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
MX2007002135A
(es)
|
2004-09-01 |
2007-04-02 |
Euro Celtique Sa |
Formas farmaceuticas de opioide que tienen una cprom y un auc en el estado estacionario proporcional a la dosis y una cmax de la dosis unica menor que la proporcional a la dosis.
|
EP2415484B1
(en)
|
2004-09-17 |
2014-06-18 |
Durect Corporation |
Sustained local anesthetic composition containing SAIB
|
US20080152595A1
(en)
*
|
2004-11-24 |
2008-06-26 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
US8481565B2
(en)
|
2004-12-27 |
2013-07-09 |
Eisai R&D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
AU2006208627B8
(en)
|
2005-01-28 |
2009-08-13 |
Mundipharma Pty Limited |
Alcohol resistant dosage forms
|
DE102005005449A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
US20060281775A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Applied Pharmacy Services, Inc. |
Two-component pharmaceutical composition for the treatment of pain
|
EP2502621A1
(en)
|
2005-06-27 |
2012-09-26 |
Valeant International (Barbados) SRL |
Crystalline forms of bupropion HBr
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
PL116330U1
(en)
*
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
EP1849460A3
(en)
*
|
2005-10-31 |
2007-11-14 |
ALZA Corporation |
Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
|
CN1957909B
(zh)
*
|
2005-10-31 |
2013-09-11 |
阿尔扎公司 |
降低鸦片样物质持续释放口服剂型的由醇诱导的剂量突然释放的方法
|
US20090317355A1
(en)
*
|
2006-01-21 |
2009-12-24 |
Abbott Gmbh & Co. Kg, |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20090022798A1
(en)
*
|
2007-07-20 |
2009-01-22 |
Abbott Gmbh & Co. Kg |
Formulations of nonopioid and confined opioid analgesics
|
US20100172989A1
(en)
*
|
2006-01-21 |
2010-07-08 |
Abbott Laboratories |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
HUE056937T2
(hu)
|
2006-02-03 |
2022-04-28 |
Opko Renal Llc |
A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
CN101400731A
(zh)
*
|
2006-03-15 |
2009-04-01 |
城北化学工业株式会社 |
稳定化的聚烯烃类树脂和聚烯烃类树脂的稳定化方法
|
US20070281016A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and surfactant
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
US20080069891A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
DK2526932T3
(en)
|
2006-06-19 |
2017-07-17 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
PT2679228T
(pt)
|
2006-06-21 |
2018-04-16 |
Opko Ireland Global Holdings Ltd |
Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
|
MX2009001294A
(es)
*
|
2006-08-04 |
2009-05-21 |
Ethypharm Sa |
Granulo y tableta que se desintegra por vía oral que comprende oxicodona.
|
JP2010501011A
(ja)
*
|
2006-08-16 |
2010-01-14 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
オピオイド鎮痛薬の調製および効用
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
JP2010522135A
(ja)
|
2006-10-09 |
2010-07-01 |
チャールストン ラボラトリーズ,インコーポレイテッド |
医薬組成物
|
DK2117521T3
(da)
|
2006-11-03 |
2012-09-03 |
Durect Corp |
Transdermale indgivelsessystemer omfattende bupivacain
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
PT2148684E
(pt)
|
2007-04-25 |
2013-04-19 |
Cytochroma Inc |
Método de tratamento para a insuficiência e deficiência de vitamina d
|
KR101959952B1
(ko)
|
2007-04-25 |
2019-03-19 |
사이토크로마 인코포레이티드 |
비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
|
WO2008134523A1
(en)
|
2007-04-25 |
2008-11-06 |
Proventiv Therapeutics, Llc |
Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
|
US8202542B1
(en)
|
2007-05-31 |
2012-06-19 |
Tris Pharma |
Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
|
WO2008148798A2
(en)
|
2007-06-04 |
2008-12-11 |
Egalet A/S |
Controlled release pharmaceutical compositions for prolonged effect
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
US20080318993A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
|
US20080318994A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
|
JP5730572B2
(ja)
*
|
2007-09-13 |
2015-06-10 |
シマ ラブス インク. |
濫用抵抗性製剤
|
ES2337935T3
(es)
|
2007-11-09 |
2010-04-30 |
Acino Pharma Ag |
Comprimidos de accion retardada con hidromorfona.
|
CA2706931C
(en)
*
|
2007-12-06 |
2015-05-12 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
EP2224808A4
(en)
*
|
2007-12-17 |
2013-11-27 |
Alpharma Pharmaceuticals Llc |
PHARMACEUTICAL COMPOSITION
|
EP2240022B1
(en)
|
2008-01-09 |
2016-12-28 |
Charleston Laboratories, Inc. |
Bilayered tablets comprising oxycodone and promethazine
|
EP2249811A1
(en)
|
2008-01-25 |
2010-11-17 |
Grünenthal GmbH |
Pharmaceutical dosage form
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
JP2011511782A
(ja)
|
2008-02-12 |
2011-04-14 |
アボット・ラボラトリーズ |
長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
|
KR101094231B1
(ko)
|
2008-02-18 |
2011-12-14 |
하나제약 주식회사 |
서방성 고형 제제 및 그의 제조방법
|
WO2009114648A1
(en)
|
2008-03-11 |
2009-09-17 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
WO2009124210A1
(en)
|
2008-04-02 |
2009-10-08 |
Cytochroma Inc. |
Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
|
US20100076249A1
(en)
*
|
2008-04-24 |
2010-03-25 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20090271009A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination treatment modification methods and systems
|
US20100017001A1
(en)
*
|
2008-04-24 |
2010-01-21 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US9282927B2
(en)
|
2008-04-24 |
2016-03-15 |
Invention Science Fund I, Llc |
Methods and systems for modifying bioactive agent use
|
US20100041964A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US20100022820A1
(en)
*
|
2008-04-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US9449150B2
(en)
*
|
2008-04-24 |
2016-09-20 |
The Invention Science Fund I, Llc |
Combination treatment selection methods and systems
|
US8876688B2
(en)
*
|
2008-04-24 |
2014-11-04 |
The Invention Science Fund I, Llc |
Combination treatment modification methods and systems
|
US20100069724A1
(en)
*
|
2008-04-24 |
2010-03-18 |
Searete Llc |
Computational system and method for memory modification
|
US20090312668A1
(en)
*
|
2008-04-24 |
2009-12-17 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20100081861A1
(en)
*
|
2008-04-24 |
2010-04-01 |
Searete Llc |
Computational System and Method for Memory Modification
|
US20090270694A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US20100081860A1
(en)
*
|
2008-04-24 |
2010-04-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational System and Method for Memory Modification
|
US20090270688A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for presenting a combination treatment
|
US9662391B2
(en)
*
|
2008-04-24 |
2017-05-30 |
The Invention Science Fund I Llc |
Side effect ameliorating combination therapeutic products and systems
|
US20100042578A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20100100036A1
(en)
*
|
2008-04-24 |
2010-04-22 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational System and Method for Memory Modification
|
US9560967B2
(en)
*
|
2008-04-24 |
2017-02-07 |
The Invention Science Fund I Llc |
Systems and apparatus for measuring a bioactive agent effect
|
US9064036B2
(en)
*
|
2008-04-24 |
2015-06-23 |
The Invention Science Fund I, Llc |
Methods and systems for monitoring bioactive agent use
|
US20100125561A1
(en)
*
|
2008-04-24 |
2010-05-20 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20100280332A1
(en)
*
|
2008-04-24 |
2010-11-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring bioactive agent use
|
US9026369B2
(en)
*
|
2008-04-24 |
2015-05-05 |
The Invention Science Fund I, Llc |
Methods and systems for presenting a combination treatment
|
US20100041958A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc |
Computational system and method for memory modification
|
US20100130811A1
(en)
*
|
2008-04-24 |
2010-05-27 |
Searete Llc |
Computational system and method for memory modification
|
US9239906B2
(en)
*
|
2008-04-24 |
2016-01-19 |
The Invention Science Fund I, Llc |
Combination treatment selection methods and systems
|
US20100063368A1
(en)
*
|
2008-04-24 |
2010-03-11 |
Searete Llc, A Limited Liability Corporation |
Computational system and method for memory modification
|
US9649469B2
(en)
*
|
2008-04-24 |
2017-05-16 |
The Invention Science Fund I Llc |
Methods and systems for presenting a combination treatment
|
US20090269329A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination Therapeutic products and systems
|
US20090271375A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination treatment selection methods and systems
|
US8930208B2
(en)
*
|
2008-04-24 |
2015-01-06 |
The Invention Science Fund I, Llc |
Methods and systems for detecting a bioactive agent effect
|
US20090271347A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring bioactive agent use
|
US20100004762A1
(en)
*
|
2008-04-24 |
2010-01-07 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20090271122A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US20090312595A1
(en)
*
|
2008-04-24 |
2009-12-17 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for memory modification
|
EP2273983B1
(en)
|
2008-05-09 |
2016-07-20 |
Grünenthal GmbH |
Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
|
US20090291975A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Warren Stern |
Dual opioid pain therapy
|
CN105456267A
(zh)
*
|
2008-07-07 |
2016-04-06 |
欧洲凯尔特公司 |
阿片类拮抗剂治疗尿潴留的用途
|
US20100260844A1
(en)
*
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
WO2010089132A1
(en)
|
2009-02-06 |
2010-08-12 |
Egalet A/S |
Immediate release composition resistant to abuse by intake of alcohol
|
US20120065221A1
(en)
|
2009-02-26 |
2012-03-15 |
Theraquest Biosciences, Inc. |
Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
|
MX347106B
(es)
|
2009-03-10 |
2017-04-12 |
Euro-Celtique S A * |
Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
|
US8811578B2
(en)
*
|
2009-03-23 |
2014-08-19 |
Telemanager Technologies, Inc. |
System and method for providing local interactive voice response services
|
NZ597283A
(en)
|
2009-06-24 |
2013-07-26 |
Egalet Ltd |
Controlled release formulations
|
CA2767576C
(en)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
PL2456424T3
(pl)
|
2009-07-22 |
2013-12-31 |
Gruenenthal Gmbh |
Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
|
PL2456427T3
(pl)
|
2009-07-22 |
2015-07-31 |
Gruenenthal Gmbh |
Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
|
US20110046173A1
(en)
*
|
2009-08-24 |
2011-02-24 |
Warren Charles Stern |
Combination analgesic opioid pain therapy
|
PL399450A1
(pl)
*
|
2009-08-31 |
2013-01-21 |
Depomed, Inc |
Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu
|
WO2011041414A1
(en)
|
2009-09-30 |
2011-04-07 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse
|
US20110104272A1
(en)
*
|
2009-11-05 |
2011-05-05 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US9579285B2
(en)
*
|
2010-02-03 |
2017-02-28 |
Gruenenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
EP2544667B1
(en)
*
|
2010-03-09 |
2018-11-14 |
Alkermes Pharma Ireland Limited |
Alcohol resistant enteric pharmaceutical compositions
|
US11672809B2
(en)
|
2010-03-29 |
2023-06-13 |
Eirgen Pharma Ltd. |
Methods and compositions for reducing parathyroid levels
|
JP2013526523A
(ja)
|
2010-05-11 |
2013-06-24 |
シマ ラブス インク. |
メトプロロールを含むアルコール耐性持続放出性経口剤形
|
EP2590636A1
(en)
|
2010-07-06 |
2013-05-15 |
Grünenthal GmbH |
Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
|
MX2013002293A
(es)
|
2010-09-02 |
2013-05-09 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
|
AU2011297901B2
(en)
|
2010-09-02 |
2014-07-31 |
Grunenthal Gmbh |
Tamper resistant dosage form comprising inorganic salt
|
EP2446882B8
(de)
|
2010-10-28 |
2014-02-12 |
Acino Pharma AG |
Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
|
CN103370058A
(zh)
|
2010-12-22 |
2013-10-23 |
普渡制药公司 |
包覆的抗篡改控制释放剂型
|
CA2822769C
(en)
|
2010-12-23 |
2016-10-04 |
Purdue Pharma L.P. |
Tamper resistant solid oral dosage forms
|
KR20130124551A
(ko)
|
2011-02-02 |
2013-11-14 |
알파마 파머슈티컬스 엘엘씨 |
오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
EP4011364B1
(en)
|
2011-03-23 |
2023-12-13 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods and compositions for treatment of attention deficit disorder
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
EP2726064B1
(en)
*
|
2011-06-30 |
2016-09-21 |
Develco Pharma Schweiz AG |
Controlled release oral dosage form comprising oxycodone
|
US20130028972A1
(en)
|
2011-07-29 |
2013-01-31 |
Grunenthal Gmbh |
Tamper-resistant tablet providing immediate drug release
|
PE20141638A1
(es)
|
2011-07-29 |
2014-11-22 |
Gruenenthal Chemie |
Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
|
US20130225697A1
(en)
*
|
2012-02-28 |
2013-08-29 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
WO2013153451A2
(en)
*
|
2012-04-09 |
2013-10-17 |
QRxPharma Ltd. |
Controlled release formulations of opioids
|
SG11201406025UA
(en)
|
2012-04-17 |
2014-11-27 |
Purdue Pharma Lp |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
EA201401139A1
(ru)
|
2012-04-18 |
2015-03-31 |
Грюненталь Гмбх |
Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
US9549899B2
(en)
|
2012-07-06 |
2017-01-24 |
Egalet Ltd. |
Abuse deterrent pharmaceutical compositions for controlled release
|
WO2014011830A1
(en)
|
2012-07-12 |
2014-01-16 |
Mallinckrodt Llc |
Extended release, abuse deterrent pharmaceutical compositions
|
RU2673818C2
(ru)
|
2012-11-30 |
2018-11-30 |
Экьюра Фармасьютикалз, Инк. |
Саморегулируемое высвобождение фармацевтического ингредиента
|
KR101840526B1
(ko)
|
2013-02-05 |
2018-03-20 |
퍼듀 퍼머 엘피 |
내변조성 제약 제제
|
EP2983468A4
(en)
|
2013-03-15 |
2016-09-07 |
Durect Corp |
COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
KR101847947B1
(ko)
|
2013-03-15 |
2018-05-28 |
옵코 아이피 홀딩스 Ⅱ 인코포레이티드 |
안정화되고 변형된 비타민 d 방출 제형
|
JP6445537B2
(ja)
|
2013-05-29 |
2018-12-26 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
1個または複数の粒子を含有する改変防止(tamper−resistant)剤形
|
MX2015016254A
(es)
|
2013-05-29 |
2016-04-20 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
|
JP6449871B2
(ja)
|
2013-07-12 |
2019-01-09 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
エチレン−酢酸ビニルポリマーを含有する改変防止剤形
|
CA2918004C
(en)
|
2013-07-23 |
2018-11-20 |
Euro-Celtique S.A. |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
CA2919892C
(en)
|
2013-08-12 |
2019-06-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
WO2015065547A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
JP6480936B2
(ja)
|
2013-11-26 |
2019-03-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
クライオミリングによる粉末状医薬組成物の調製
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
WO2015095391A1
(en)
|
2013-12-17 |
2015-06-25 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
AU2015237721B2
(en)
|
2014-03-26 |
2018-04-26 |
Sun Pharma Advanced Research Company Ltd. |
Abuse deterrent immediate release coated reservoir solid dosage form
|
WO2015173195A1
(en)
|
2014-05-12 |
2015-11-19 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
EP3148512A1
(en)
|
2014-05-26 |
2017-04-05 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
TWI664190B
(zh)
|
2014-06-27 |
2019-07-01 |
美商C2N醫療診斷有限責任公司 |
人類化抗-tau抗體
|
US9707184B2
(en)
|
2014-07-17 |
2017-07-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
AU2015298858A1
(en)
|
2014-08-07 |
2017-03-02 |
Opko Ireland Global Holdings Ltd. |
Adjunctive therapy with 25-hydroxyvitamin D
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
EP3209282A4
(en)
|
2014-10-20 |
2018-05-23 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
CA2936746C
(en)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2016170097A1
(en)
|
2015-04-24 |
2016-10-27 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
US11103581B2
(en)
|
2015-08-31 |
2021-08-31 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
US9943513B1
(en)
|
2015-10-07 |
2018-04-17 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
JP2019507181A
(ja)
|
2016-03-04 |
2019-03-14 |
チャールストン ラボラトリーズ,インコーポレイテッド |
医薬組成物
|
CA3018019A1
(en)
|
2016-03-28 |
2017-10-26 |
Opko Ireland Global Holdings, Limited |
Methods of vitamin d treatment
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
WO2019087084A1
(en)
|
2017-11-02 |
2019-05-09 |
Eman Biodiscoveries Sd. Bhd. |
Extract of orthosiphon stamineus, formulations, and uses thereof
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
WO2020225773A1
(en)
|
2019-05-07 |
2020-11-12 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
CA3167217A1
(en)
|
2020-01-13 |
2021-07-22 |
Durect Corporation |
Sustained release drug delivery systems with reduced impurities and related methods
|
CN115702888B
(zh)
*
|
2021-08-13 |
2024-05-28 |
合肥立方制药股份有限公司 |
一种盐酸羟考酮渗透泵缓释片及其制备方法
|